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Abstract
Background: Inhaled corticosteroid (ICS) with long-acting beta-2 agonists is a well-documented combination therapy
for chronic obstructive pulmonary disease (COPD) based on its additive anti-inflammatory properties. By contrast, the
recommendation of ICS in combination with long-acting muscarinic antagonist (LAMA) is not evidence-based. In this
study, neutrophils obtained from COPD patients were used to compare the anti-inflammatory effects of aclidinium
bromide (a long-acting muscarinic antagonist) with corticosteroids and their potential additive effect.
Methods: Human sputum and blood neutrophils were isolated from healthy individuals (n = 37), patients with stable
COPD (n = 52) and those with exacerbated COPD (n = 16). The cells were incubated with corticosteroid fluticasone
propionate (0.1 nM–1 μM), aclidinium bromide (0.1 nM–1 μM) or a combination thereof and stimulated with 1 μg of
lipopolysaccharide/ml or 5 % cigarette smoke extract. Levels of the pro-inflammatory mediators interleukin-8, matrix
metalloproteinase-9, CCL-5, granulocyte-macrophage colony-stimulating factor and interleukin-1β were measured and
the mechanisms of corticosteroid resistance evaluated at the end of the incubation.
Results: The non-neuronal cholinergic system was over-expressed in neutrophils from COPD patients, as evidenced by
increases in the expression of muscarinic receptors (M2, M4 and M5), choline acetyltransferase and vesicular acetylcholine
transporter. Aclidinium bromide demonstrated anti-inflammatory effects on neutrophils from COPD patients, reversing
their resistance to corticosteroids. Additive effects of combined aclidinium bromide and fluticasone propionate in
blocking M2 receptor levels, inhibiting phosphoinositide 3-kinase-δ and enhancing the glucocorticoid response element
transcription factor were demonstrated and were accompanied by an increase in the corticosteroid-induced expression
of anti-inflammatory-related genes.
Conclusions: LAMAs potentiate the anti-inflammatory effects of corticosteroids in neutrophils from COPD patients
in vitro, thus providing a scientific rationale for their use in combination with corticosteroids in the treatment of COPD.
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Background
Chronic obstructive pulmonary disease (COPD) is char-
acterised by airway and systemic inflammation leading
to airway remodelling and obstruction that are not
completely reversible. The current first-line maintenance
treatment for COPD involves the use of bronchodilators,
including long-acting muscarinic antagonists (LAMAs)
and long-acting beta agonists (LABAs). Inhaled cortico-
steroids (ICS), despite their good activity in asthma, are
much less effective in improving lung function and have
little or no effect in controlling the underlying chronic
inflammation in COPD [1]. Combined therapies, consist-
ing of ICS + LABAs, LABA + LAMA, as well as LAMA
monotherapy are common options for COPD patients at
increased risk of an exacerbation of moderate symptoms
[2–4]. Triple therapy based on ICS in combination with
LABAs and LAMAs is indicated in patients with severe
COPD who are at risk of disease exacerbation [5]. In the
latter patients, the effective agents include the
phosphodiesterase 4 (PDE4) inhibitor roflumilast, an
anti-inflammatory agent used to reduce exacerbations of
chronic bronchitis [6].
The rationale for drug combinations to achieve additive
or synergistic effects in the treatment of COPD comes
from clinical randomised studies and can be explained by
pharmacologic molecular interactions. Thus, for example,
LABAs increase corticosteroid responsiveness by revers-
ing glucocorticoid receptor alpha (GRα) phosphorylation
at serine 226 (Ser226) and promoting GRα nuclear
translocation [7, 8]. Recent evidence indicates that LABAs
reverse corticosteroid insensitivity by attenuating oxidative
stress and inhibiting phosphoinositide-3-kinase delta
(PI3Kδ), thus allowing the efficient action of histone
deacetylase-2 (HDAC2) and GRα [9]. These mechanisms,
which are shared with theophylline [7] and, as shown
recently, roflumilast [10], explain the clinical benefits of
combination therapy to improve corticosteroid anti-
inflammatory effects in COPD. However, the use of
LAMAs + ICS is thus far not evidence-based, although its
potential efficacy is suggested by the current Global Initia-
tive for Chronic Obstructive Lung Disease (GOLD 2015)
guidelines.
COPD is associated with increased pulmonary vagal ac-
tivity [11]. Muscarinic antagonists are effective drugs for
the treatment of COPD because their anticholinergic
effect results in the relaxation of airway smooth muscle
[12]. In addition, a non-neuronal cholinergic system has
been demonstrated in human airway epithelial cells [13],
lung fibroblasts [14], alveolar macrophages [15] and spu-
tum neutrophils [16] and represents a previously unappre-
ciated regulatory pathway in pulmonary inflammation and
remodelling. Because dysfunction of the non-neuronal
cholinergic system appears to be involved in the patho-
physiology of COPD [17], the potential anti-inflammatory
and anti-remodelling effects of muscarinic antagonists,
shown in preclinical models [18], may be of added value
to their established bronchodilation in the management of
chronic respiratory diseases. The persistent activation of
neutrophils, as the primary effector cell involved in the in-
flammatory process of COPD, contributes to its pathogen-
esis [19]. Current anti-inflammatory therapies based on
corticosteroids poorly regulate neutrophil activation,
which has limited their clinical effectiveness [10, 20]. The
aim of this study was to provide scientific evidence of the
anti-inflammatory effects of the anticholinergic agent acli-
dinium bromide in the corticosteroid-insensitive neutro-
phils from COPD patients. Our results provide support
for the scientific rationale regarding the use of combined
LAMAs and ICS therapy in patients with COPD.
Methods
All reagents were obtained from Sigma-Aldrich (St. Louis,
MO, USA) unless otherwise stated.
Patients
Sputum neutrophils, peripheral blood neutrophils and
whole blood were obtained from COPD patients who
were smokers and from healthy non-smoking controls.
The study population consisted of 52 patients with
stable COPD, defined according to the 2013 GOLD
guidelines, 16 patients with severe exacerbated COPD
and 37 age-matched non-smoking healthy controls with
normal lung function. Neutrophils from patients with
stable COPD were used in the mechanistic experiments,
and those from patients with exacerbated COPD to
measure the basal expression of non-neuronal choliner-
gic components in neutrophils. All patients with exacer-
bated disease were hospitalised because of airway
bacterial infections, confirmed by bacteriological analysis
of blood and sputum. Cell samples from patients with
exacerbated COPD were collected before starting treat-
ment with oral corticosteroids. The minimum washout
period in stable COPD patients for sampling sputum or
blood was 4 days, which avoided effects of chronic medi-
cation on the results. All COPD patients were current
smokers and had bronchitis. In the patients with stable
COPD, there were no disease exacerbations within
2 weeks prior to sample collection. Routine lung
function tests were performed to evaluate forced vital
capacity (FVC), forced expiratory volume in one second
(FEV1) and FEV1/FVC ratio using a Vitalograph® αIII
spirometer (Vitalograph, Maids Moreton, UK). The clin-
ical features of the study population are summarised in
Table 1. This project was approved by the local Ethics
Committee of the University General Hospital of
Valencia, Spain. Written informed consent was obtained
from each patient or volunteer before starting sputum/
blood sampling and lung function testing.
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Human neutrophil isolation
Neutrophils were isolated from peripheral venous blood
and cultured as previously outlined [21], using 3 % dex-
tran 500 (in 0.9 % saline) together with Ficoll-Paque His-
topaque 1077 (Amersham Pharmacia Biotech, Barcelona,
Spain) at a ratio of 2:1. The neutrophil preparations were
>97 % pure as assessed by Giemsa staining and had via-
bility of >99 % as measured by trypan blue exclusion.
Neutrophils from spontaneous sputum (~2 ml) were col-
lected from patients with stable and exacerbated COPD
and processed with dithiothreitol using established
methods [22]. Sputum cell pellets were resuspended in
RPMI 1640 supplemented with 10 % foetal calf serum,
1 % penicillin-streptomycin and 1 mmol L-glutamine/L
at a concentration of 1 × 106 cells/ml. An aliquot con-
taining 4 × 105 cells was incubated on a 24-well plate for
1 h at 37 °C in humidified 5 % CO2. Preparations con-
taining < 95 % neutrophils were discarded. Neither the
purity nor the viability of the cell preparations was af-
fected by the different experimental conditions of the
study.
Preparation of cigarette smoke extract solutions
Cigarette smoke extract (CSE) was prepared as previ-
ously outlined [23]. Briefly, the smoke of a research
cigarette (2R4F; Tobacco Health Research, University of
Kentucky, Lexington, KY, USA) was generated by a re-
spiratory pump (Rodent Respirator 680; Harvard Appar-
atus, March-Hugstetten, Germany) through a puffing
mechanism mimicking the human smoking pattern (3
puffs/min; 1 puff 35 ml; each puff of 2 s duration,
0.5 cm above the filter) and was bubbled into a flask
containing 25 ml of pre-warmed (37 °C) RPMI 1640 cul-
ture medium. The resulting CSE solution was considered
as 100 % CSE and used for experiments within 30 min
of preparation. CSE 10 % corresponded approximately to
the exposure associated with smoking two packs of ciga-
rettes per day [24]. To test for cytotoxicity/apoptosis in-
duced by CSE, isolated neutrophils were treated with
CSE concentrations of up to 5 % for 6 h. No significant
difference in the lactate dehydrogenase level (lactate
dehydrogenase cytotoxicity assay; Cayman Chemical,
Madrid, Spain) or annexin V-FITC was observed
between the CSE and control groups (data not shown).
Cell stimulations and cytokine assays
Sputum and peripheral blood neutrophils were adjusted
to 500 × 103 cells per well in 24-well plates and incubated
in RPMI 1640 for 1 h at 37 °C, 5 % CO2. The cells were
then left untreated or treated with long-acting muscarinic
antagonist aclidinium bromide (0.1 nM–1 μM; Almirall
Laboratories, Barcelona, Spain), muscarinic antagonist at-
ropine (0.1 nM–1 μM), corticosteroid fluticasone propion-
ate (0.1 nM–1 μM), long-acting beta 2 agonist formoterol
(0.01 nM–100 nM), long-acting beta 2 agonist salmeterol
(0.1 nM–1 μM), the muscarinic receptor type 3 (M3) in-
hibitor p-fluoro-hexahydrosiladifenidol (pFHHSid; 10 nM,
1 μM), the M2 inhibitor methoctramine (100 nM, 1 μM),
the PI3K inhibitor LY294002 (1 μM) or the nicotinic re-
ceptor antagonist hexamethonium (100 μM) for 1 h before
they were stimulated with 1 μg of lipopolysaccharide
(LPS)/ml), CSE 5 % or 10 μM carbachol. In other
Table 1 Clinical features. COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in one second; FVC: forced
vital capacity; Pack-yr = 1 year smoking 20 cigarettes-day. Data are mean ± SD. *P < 0.05 related to Healthy subjects
Healthy
(n = 37)
Stable COPD
(n = 52)
Exacerbated COPD
(n = 16)
Age, yr 66.1 ± 6 65.1 ± 14 63.8 ± 8.4
Sex (M/F) 27/10 35/17 12/4
Tobacco consumption, pack-yr 0 35.2 ± 6* 42.3 ± 13*
FEV1, % pred 98 ± 3 53.2 ± 3* 38.0 ± 13*
FVC, % pred 96 ± 4 90.2 ± 6 89.5 ± 8
FEV1/FVC % 98 ± 3 50.1 ± 6* 46.2 ± 9*
GOLD 1 (mild) patients, no. 0 0 0
GOLD 2 (moderate) patients, no. 0 36 3
GOLD 3 (severe) patients, no. 0 16 10
GOLD 4 (very severe) patients, no. 0 0 3
Receiving inhaled steroids, no. 0 26 16
Receiving theophyllines, no. 0 0 0
Receiving long-acting b2-agonist, no. 0 49 16
Receiving anticholinergics, no. 0 41 13
Total peripheral blood neutrophils 4.2 ± 0.3 x 109/L 8.2 ± 1.3 x 109/L* 9.9 ± 0.2 x 109/L*
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experiments, 10 U of acetylcholinesterase (ACheE)/ml
was added 1 h before the stimulus to remove extracellular
acetylcholine and during the 6-h period of LPS or CSE
stimulation. CSE 5 % was selected as a stimulus in sputum
neutrophils because LPS alone did not increase interleukin
(IL)-8 levels over basal values, as previously reported [25].
The stimuli and drugs were incubated together with
the cells for 6 h. Supernatants were collected and centri-
fuged at 120 × g for 5 min. The cell-free supernatant was
used to measure IL-8, metalloproteinase-9 (MMP9),
CCL-5, granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF) and IL-1β. Cellular extracts were used to
measure mRNA expression after 6 h of cell stimulation.
IL-8 levels were measured using a commercially avail-
able enzyme-linked immunosorbent assay kit for IL-8
(R&D Systems, Nottingham, UK) according to the man-
ufacturer’s protocol. MMP9, CCL-5, GM-CSF and IL-1β
were measured using LUMINEX technology, in accord-
ance with the manufacturer’s protocol.
Real-time RT-PCR and siRNA experiments
Total RNA was isolated from sputum or peripheral
blood neutrophils using the TriPure® isolation reagent
(Roche, Indianapolis, IN, USA). The integrity of the
extracted RNA was confirmed with Bioanalyzer (Agilent,
Palo Alto, CA, USA). Reverse transcription was
performed using 300 ng of total RNA with a TaqMan
reverse transcription kit (Applied Biosystems, Perkin-
Elmer Corporation, CA, USA). cDNA was amplified
using specific primers together with probes predesigned
by Applied Biosystems for organic transporter cation 1
(OTC1; cat. no. Hs00222691_m1), OTC2 (cat. no.
Hs01010726_m1), OTC3 (cat. no. Hs00427552_m1), cho-
line acetyltransferase (ChAT; cat. no. Hs00252848_m1),
high-affinity choline transporter (ChT1; cat. no.
Hs00222367_m1), M1 (cat. no. Hs00265195_s1), M2 (cat.
no. Hs00265208_s1), M3 (cat. no. Hs00265216_s1), M4
(cat. no. Hs00265219_s1), M5 (cat. no. Hs00255278_s1),
β2 adrenergic receptor (β2ADR; cat. no. Hs00240532_s1),
vesicular acetylcholine transporter (cat. no. VAChT;
Hs00268179_s1), macrophage migration inhibitory factor
(MIF; cat. no. Hs00236988), mitogen-activated protein
kinase phosphatase 1 (MKP-1; cat. no. Hs00610256),
PI3K-δ (cat. no. Hs00192399), HDAC2 (cat. no.
Hs00231032), GRα (cat. no. Hs00353740_m1), cysteine-
rich secretory protein LCCL domain-containing 2
(CRISPLD2; cat. no. Hs00230322_m1) and glucocorticoid-
induced leucine zipper (GILZ; cat. no. Hs00608272_m1)
genes in a 7900HT Fast Real-Time PCR system (Applied
Biosystems) using Universal Master Mix (Applied
Biosystems).
Expression of the target gene was reported as the fold in-
crease or decrease relative to the expression of GAPDH as
an endogenous control (Applied Biosystems; 4310884E).
The mean value of the replicates for each sample was cal-
culated and expressed as the cycle threshold (Ct). The
level of gene expression was then calculated as the differ-
ence (ΔCt) between the Ct value of the target gene and the
Ct value of GAPDH. The fold changes in the target gene
mRNA levels were expressed as 2−ΔCt.
Small interfering RNA (siRNA), including the
scrambled siRNA control, was purchased from Ambion
(Huntingdon, Cambridge, UK). Cultured human bron-
chial epithelial cells Beas2B were transfected with 50 nM
of a commercial siRNA against the M2 (PN 4392421;
Ambion, Austin TX, USA) or M3 (PN 4390815;
Ambion, Austin TX, USA) gene or with 50 nM of the
siRNA control (Ambion, Huntingdon, Cambridge, UK)
in serum-free and antibiotic-free medium. After 6 h, the
medium was aspirated and replaced with medium con-
taining serum for a further 48 h. Lipofectamine-2000
(Invitrogen, Paisley, UK), at a final concentration of
2 μg/mL, was used as the transfection reagent.
Glucocorticoid response element transfection assay
Beas2B epithelial cells were seeded (40,000 cells/well)
and cultured for 24 h under a 5 % CO2/air atmosphere
at 37 °C in 96-well plates containing Dulbecco’s modified
Eagle’s medium (DMEM). The Cignal GRE reporter
assay kit (Qiagen, cat. no. 336841) was used to monitor
the activity of glucocorticoid receptor-induced signal
transduction pathways in cultured cells, following the
manufacturer’s indications. First, the cells were
transfected with M2- or M3-gene-targeted siRNA or the
scrambled siRNA control as described above. After 24 h,
the cells were transfected with Cignal reporter (100 ng),
the Cignal negative control (100 ng) and the Cignal posi-
tive control (100 ng) in Opti-MEM serum-free culture
medium using Lipofectamine 2000 (Invitrogen) as the
transfection reagent. Subsequently, the cells were incu-
bated with the transfection reagents at 37 °C in a 5 %
CO2 incubator for 16 h and then pre-incubated for an-
other 6 h with different fluticasone propionate and drug
combinations at different concentrations in DMEM.
After the second 6-h incubation, the luciferase assay
was developed using the Dual-Luciferase Reporter Assay
system (Promega, cat. no. 1910) following the manufac-
turer’s protocol. In brief, the growth medium was
removed from the cultured cells, which were then
washed gently with phosphate-buffered saline (PBS).
After complete removal of the rinse solution, passive
lysis buffer 1× was added. The culture plate was then
placed on an orbital shaker for gentle shaking at room
temperature for 15 min. The luciferase assay reagent II
(LAR II) was prepared by resuspending the provided lyo-
philised luciferase assay substrate in 10 mL of the sup-
plied luciferase assay buffer II. One hundred microliters
of LAR II was predispensed into the appropriate number
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of wells of a white 96-well plate, followed by 20 μl of cell
lysate and mixing by pipetting two or three times. The
assay plate was placed in a luminometer (Victor
Luminometer, Perkin-Elmer, Madrid, Spain) and firefly
luciferase activity was measured. Just before use, the
Stop & Glo reagent was prepared by diluting 1 volume
of the Stop & Glo substrate with 50 volumes of Stop &
Glo buffer. After the measurement of luciferase activity,
100 μl of Stop & Glo reagent was dispensed in the corre-
sponding wells and a second luminometer reading was
initiated, recording Renilla luciferase activity. The data
are expressed as 2× the GRE-reporter fold induction of
luciferase relative to that of unstimulated cells.
Western blot
Western blot analysis was used to detect changes in
p-ERK1/2, p-p38, MKP1 and phospho-serine 226-GR.
Neutrophils incubated in RPMI 1640 were treated with
fluticasone propionate, aclidinium bromide or a combin-
ation thereof for 1 h and stimulated with LPS for
30 min. The cells were then centrifuged and total
protein was extracted as previously outlined [26].
Electrophoresis was carried out using 20 μg of protein
(denatured) and a molecular mass protein marker (Bio-Rad
Kaleidoscope marker; Bio-Rad Laboratories Ltd.) loaded
onto an acrylamide gel consisting of a 5 % acrylamide stack-
ing gel and a 10 % acrylamide resolving gel. After electro-
phoresis at 100 V for 1 h, the proteins were transferred
from the gel to a polyvinylidene difluoride membrane using
a wet blotting method. The membrane was blocked with
5 % Marvel in PBS containing 0.1 % Tween20 (PBS-T),
probed with a rabbit anti-human p-ERK1/2 (1:1000) anti-
body (monoclonal antibody; Cell Signaling, Boston, MA,
USA; cat. no. 4376S) and normalised to total rabbit anti-
human ERK1/2 (1:1000) antibody (monoclonal antibody;
Cell Signaling; cat. no. 4695); rabbit anti-human phospho-
p38 (1:1000) antibody (monoclonal antibody; Cell Signaling;
cat. no. 4631) normalised to total rabbit anti-human p38
(1:1000) antibody (monoclonal antibody; Cell Signaling; cat.
no. 9212); rabbit anti-human polyclonal MKP1 (1:1000)
antibody (Assay Biotech; cat. no. B1099) normalised to total
mouse anti-human β-actin (1:10,000) antibody (monoclonal
antibody; cat. no. A1978; Sigma); or rabbit anti-human
polyclonal phospho-GR-Ser226 (1:1000) antibody (Novus
Biologicals, Littleton, CO, USA; cat. no. NB100-92540),
rabbit anti-human polyclonal M1 (1:1000) antibody (Sigma;
cat. no. M9808), rabbit anti-human polyclonal M2 (1:1000)
antibody (Sigma; cat. no. M9558), rabbit anti-human
polyclonal M3 (1:1000) antibody (Sigma; cat. no. M0194),
mouse anti-human monoclonal M4 (1:1000) antibody
(Merck Millipore, Madrid, Spain; cat no. MAB1576), or
rabbit anti-human polyclonal M5 (1:1000) antibody (Novus
Biologicals; cat. no. NBP1-00907) normalised to mouse
anti-human monoclonal GRα (1;1000) antibody (BD
Biosciences, Franklin Lakes, NJ, USA; cat. no. 611227). The
enhanced chemiluminescence method of protein detection
(ECL Plus; Amersham GE Healthcare, Little Chalfont, UK)
was used to detect labelled proteins. Protein expression was
quantified by densitometry relative to normalised antibody
expression using the software GeneSnap version 6.08. The
results are expressed as ratios of the endogenous controls
as appropriate.
PI3Kδ activity
To measure PI3Kδ activity, neutrophils from COPD pa-
tients were isolated and then incubated with aclidinium
bromide (10 nM), atropine (100 nM), LY294002 (1 μM),
methoctramine (1 μM) or pFHHSid (1 μM) for 1 h. The
cells were stimulated with LPS for 30 min and then cen-
trifuged. Total protein was extracted and the amount
measured using the Bio-Rad assay (Bio-Rad Laboratories
Ltd., Hemel Hempstead, UK) to ensure equal amounts
(500 μg) in the immunoprecipitation reaction with
anti-PI3-kinase δ antibody (p110δ; ab32401; Abcam,
Cambridge, UK). PI3K activity was measured using the
PI3-kinase activity ELISA (cat. no. k-1000s; Echelon Bio-
science, Salt Lake City, UT, USA), in accordance with
the manufacturer’s protocol. In brief, PI3-K reactions
were run with the class I PI3-K physiological substrate
PI [4, 5] P2 (PIP2). The enzyme reactions, PIP3 stan-
dards and controls were then mixed and incubated with
PIP3 binding protein, which is highly specific and
sensitive to PIP3. This mixture was transferred to a
PIP3-coated microplate for competitive binding and the
amount of PIP3 produced by PI3-K was then detected,
using a peroxidase-linked secondary detector and col-
ourimetric detection, comparing the enzyme reactions
with a PIP3 standard curve. The results are expressed as
pmol PI [3–5] P3 per mg of protein.
Data analysis
The data were subjected to a parametric analysis, with
p < 0.05 considered indicative of statistical significance.
Parametric data are expressed as the mean ± SD of n ex-
periments using a Student’s t-test and one-way or two-way
analysis of variance (ANOVA) followed by a Bonferroni
post hoc test. The concentration of aclidinium bromide,
fluticasone propionate, formoterol or salbutamol produ-
cing 50 % inhibition (IC50) was calculated from the
concentration-response curves by nonlinear regression in
neutrophils from healthy individuals and COPD patients.
Results
Basal activation of non-neuronal cholinergic system com-
ponents in neutrophils from COPD patients
Basal levels of the mRNA and protein of muscarinic re-
ceptor subtypes M2 and M4 were expressed in neutro-
phils from healthy individuals and from patients with
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stable COPD and induced in neutrophils from patients
with exacerbated disease, in both peripheral blood and
sputum (Fig. 1). M3 and M5 were detected at low levels
but induced in neutrophils from patients with exacerbated
COPD, while M1 expression was virtually absent. ChAT,
the enzyme responsible for the generation of intracellular
acetylcholine, was detected in blood and sputum
neutrophils from healthy individuals and increased in
COPD patients (Fig. 1). VAChT, responsible for loading
acetylcholine into secretory organelles, was over-
expressed in neutrophils from COPD patients (Fig. 1).
OCT1, the transmembrane protein that transports acetyl-
choline, was detected at low levels but increased in COPD
patients, while OCT2 and OCT3 were not detected
(Fig. 1), nor was the high-affinity choline transporter
ChT1. Beta 2 adrenoreceptor (β2-ADR) was detected in
neutrophils from healthy donors and over-expressed in
neutrophils from COPD patients, while there was no dif-
ference in GRα expression between groups. By contrast,
MKP1 was down-regulated in neutrophils from patients
with stable and exacerbated COPD (Fig. 1).
Inhibition of neutrophil response by aclidinium bromide
and fluticasone propionate
In peripheral blood neutrophils from healthy controls,
fluticasone propionate (0.1 nM–1 μM) concentration-
dependently inhibited the cytokine secretion induced by
LPS (1 μg/ml), nearly completely suppressing IL-8,
MMP9, GM-CSF and to a lesser extent IL-1β and
CCL-5 secretion (Fig. 2a, Additional file 1: Table SE1).
By contrast, the inhibitory effect of fluticasone propion-
ate was impaired in neutrophils from COPD patients,
with less than half of the percent maximum effect ob-
served in healthy control neutrophils; the exception was
CCL-5 (Fig. 2a, Additional file 1: Table SE1). Aclidinium
bromide was less effective than fluticasone propionate in
inhibiting cytokine secretion in neutrophils from healthy
individuals, achieving 72, 50, 46, 39 and 33 % of the
maximal inhibition for IL-8, MMP9, IL-1β, CCL-5 and
GM-CSF, respectively; however, in neutrophils from
COPD patients, it exhibited similar inhibitory effects. In
sputum neutrophils from COPD patients stimulated with
CSE 5 %, < 40 % of maximal IL-8 inhibition was achieved
with fluticasone propionate (Fig. 2b, Additional file 1:
Table SE1), whereas aclidinium bromide concentration-
dependently inhibited CSE-induced IL-8 secretion in spu-
tum neutrophils of COPD patients with similar potency
and maximal effects observed in peripheral neutrophils
from healthy and COPD patients. Aclidinium bromide
also significantly inhibited basal IL-8 secretion in unstimu-
lated sputum cells (Fig. 2b, Additional file 1: Table SE1).
Formoterol exerted pro-inflammatory effects on IL-8,
Fig. 1 Expression of non-neuronal cholinergic system components in human neutrophils from healthy controls and COPD patients with stable
and exacerbated disease. a Peripheral blood or b sputum neutrophils were isolated from healthy controls (n= 24) and patients with stable (n= 30) and
exacerbated (n= 16) COPD. mRNA expression was measure by RT-PCR and quantified according to the 2−ΔCt method, with expression of the
housekeeping gene GAPDH serving as an internal control. Protein expression was measured by western blot and quantified based on the intensity of the
target protein and the internal control β-actin. Representative images are shown. Data are presented as the mean ± SD. One-way repeated measures
analysis of variance followed by post hoc Bonferroni tests: *p< 0.05 vs. healthy controls; #p< 0.05 vs. patients with stable COPD
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GM-CSF and IL-1β secretion in both peripheral blood
and sputum neutrophils from healthy controls and COPD
patients (Fig. 2b, Additional file 2: Figure SE1 and
Additional file 1: Table SE1), while salmeterol showed
weak inhibitory or pro-inflammatory effects depending on
the measured cytokine (Fig. 2b, Additional file 2: Figure
SE1 and Additional file 1: Table SE1). The pro-
inflammatory actions of formoterol and salmeterol were
inhibited by propranolol, which implied a role for β2-ADR
(data not shown).
Effect of the combination of aclidinium bromide and
fluticasone propionate on neutrophil response
Whether the anti-inflammatory effects of aclidinium brom-
ide and fluticasone propionate are additive was tested using
suboptimal concentrations of the drugs based on their
concentration-dependent inhibitory curves. In peripheral
blood neutrophils, the combination of fluticasone propion-
ate (1 nM) and aclidinium bromide (10 nM) showed
additive effects, resulting in nearly 50 % inhibition of LPS-
induced IL-8, CCL-5, GM-CSF and IL-1β, but not MMP9
(Fig. 3). Suboptimal concentrations of fluticasone propion-
ate in combination with 100 nM of the M2 inhibitor meth-
octramine [27] reproduced the additive effects observed
with aclidinium bromide, whereas this was not the case
with the M3 inhibitor pFHHSid (Fig. 3). Similar results
were obtained in sputum neutrophils from COPD patients.
Non-neuronal cholinergic activation in neutrophils from
COPD patients
The muscarinic receptor agonist carbachol was used as a
stimulus to explore functional muscarinic receptor
activation in neutrophils. Carbachol (10 μM) induced
IL-8 release in isolated blood and sputum neutrophils.
This effect was concentration-dependently inhibited by
aclidinium bromide but not by hexamethonium (Fig. 4),
which ruled out the involvement of nicotinic receptors.
To eliminate the contribution of extracellular acetylcho-
line to neutrophil activation, acetylcholinesterase was
added 1 h before and again during neutrophil stimula-
tion with LPS or CSE. Acetylcholinesterase attenuated
the IL-8 release induced by LPS in peripheral blood neu-
trophils and by CSE in the sputum neutrophils of COPD
patients, suggesting a role for extracellular acetylcholine
in neutrophil activation (Fig. 4).
Mechanisms involved in the improved anti-inflammatory
effects of fluticasone propionate when combined with
aclidinium bromide in neutrophils from COPD patients
In peripheral blood neutrophils from COPD patients, the
combination of fluticasone propionate and aclidinium
bromide did not affect the expression of corticosteroid
modulator molecules including macrophage migration
inhibitory factor (MIF), HDAC2 and GRα. However,
together the two drugs increased the expression of the
Fig. 2 Aclidinium bromide shows anti-inflammatory properties in human neutrophils. Concentration-dependent inhibition of a lipopolysaccharide
(LPS)- or b cigarette smoke extract (CSE)-induced cytokines or MMP-9 release by aclidinium bromide (Acl), fluticasone propionate (Flu), salmeterol
(Salm) or formoterol (Form) from a peripheral blood and b sputum neutrophils of healthy controls and COPD patients. Neutrophils were preincubated
with Acl (0.1 nM–1 μM), Flu (0.1 nM–1 μM), Salm (0.1 nM–1 μM) or Form (0.01–100 nM) for 1 h followed by cell stimulation with LPS (1 μg/ml) or CSE
(5 %) for 6 h. The results are expressed as the mean ± SD (n = 4 each for cells from healthy controls and COPD patients in independent experiments
with triplicate samples). A two-way ANOVA was followed by a post hoc Bonferroni test. *p < 0.05 vs. cells from COPD patients; #p < 0.05 vs. basal values
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corticosteroid-inducible genes MKP1, CRISPLD2 and GILZ
to a greater extent than achieved with fluticasone propion-
ate monotherapy (Fig. 5), consistent with the increased acti-
vation of the glucocorticoid response element (GRE).
To corroborate this hypothesis, bronchial epithelial cells
Beas2B were transfected with a GRE reporter construct.
Treatment of these 2xGRE-Beas2B reporter cells with
dexamethasone (0.1 nM–1 μM) for 6 h induced GRE-
dependent transcription in a concentration-dependent
manner (Fig. 6a). Neither aclidinium bromide nor atropine
as monotherapy modified the GRE signal (Fig. 6a), whereas
it was increased significantly by combinations of increasing
concentrations of aclidinium bromide, atropine or the PI3K
inhibitor LY294002 with a fixed (1 nM) concentration of
fluticasone propionate (Fig. 6b). Similar results were
obtained with combinations of fixed concentrations of acli-
dinium bromide (10 nM) or LY294002 (1 μM) with increas-
ing concentrations of fluticasone propionate (Fig. 6c). In
siRNA-M2 cells, fluticasone-propionate-induced GRE
activation was higher than in siRNA-M3 or control
siRNA(−) cells, suggesting the participation of M2
receptors (Fig. 6d). Aclidinium bromide, atropine, methoc-
tramine and LY294002 (but not pFHHSid) inhibited
LPS-induced PI3Kδ activity in COPD blood neutrophils
(Fig. 6e). Additional mechanistic investigations showed that
aclidinium bromide in combination with fluticasone propi-
onate potentiated the inhibition of p-ERK1/2, p-p38 and
GRser226 and increased the expression of MKP1 over the
level achieved with either drug alone (Fig. 7).
Discussion
This study provided novel evidence of the additive anti-
inflammatory properties of aclidinium bromide and flutica-
sone propionate in neutrophils from COPD patients. It thus
establishes a scientific rationale for future clinical research
with ICS/LAMA combinations in COPD. We also
demonstrated activation of the non-neuronal cholinergic
system in the blood and sputum neutrophils of COPD
patients and the effective reduction of cytokine and
metalloproteinase release in aclidinium-bromide-treated
neutrophils from COPD patients. The combination of
aclidinium bromide and fluticasone propionate increased
the impaired anti-inflammatory properties of the latter drug
by a mechanism involving the inhibition of GRα phos-
phorylation at Ser-226, the enhancement of fluticasone-
propionate-mediated GRE activation and the expression of
corticosteroid-dependent anti-inflammatory genes includ-
ing MKP1, CRISPLD2 and GILZ.
Fig. 3 Effects of combined aclidinium bromide and fluticasone propionate on inflammatory cytokines in neutrophils from COPD patients. a
Peripheral blood or b sputum neutrophils from healthy controls and COPD patients were incubated with aclidinium bromide (Acl), fluticasone
propionate (Flut) or both for 1 h before they were stimulated with a lipopolysaccharide (LPS) or b cigarette smoke extract (CSE) for 6 h. Cytokine
release was measured in cell supernatants. The results are expressed as the mean ± SD (n = 4 each for cells from healthy controls and COPD
patients in independent experiments with triplicate samples). A two-way ANOVA was followed by a post hoc Bonferroni test. *p < 0.05 vs. control
unstimulated cells; #p < 0.05 vs. stimulated cells. ⊥ p < 0.05 vs. monotherapy
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In the treatment of mild to severe COPD, ICS in com-
bination with LABAs plays an essential role in patients at
risk of disease exacerbation. Although recent randomised
clinical trials showed that ICS withdrawal did not increase
the number of exacerbations in patients with severe
COPD under LABA/LAMA/ICS triple therapy [28], the
reduced FEV1 and impaired quality of life after ICS
cessation provided evidence of the benefit of ICS in COPD
[28, 29]. However, ICS monotherapy is not indicated; in-
stead, the combination of ICS with LABAs has been
broadly prescribed as it is more effective than either agent
alone in improving lung function and health status and in
reducing exacerbation in patients with moderate to very
severe COPD [2]. Nonetheless, the recommendation for
combined ICS/LAMA is not evidence-based.
The presence of a non-neuronal cholinergic system in
the alveolar macrophages and neutrophils of COPD
patients has been implicated in the pathogenesis of the
disease [15, 16]. It was reported that activation of M1,
M2 and M3 receptors occurred in the sputum neutro-
phils of COPD patients by the addition of exogenous
acetylcholine [16]. Immunocytochemistry demonstrated
the reduced expression of M2 in COPD compared with
that in healthy neutrophils and an increase in M3 ex-
pression [16]. In the present work, by fully characterising
the non-neuronal cholinergic system in blood and spu-
tum neutrophils from healthy controls and in COPD pa-
tients, we found that M2 was more highly expressed in
patients with stable disease and over-expressed in those
with exacerbated disease. Similar results were obtained
for M4, to a lesser extent for M5 and to a very slight ex-
tent for M3. The discrepancy with the previous report
regarding M2 expression might be explained by the dif-
ferent techniques and antibodies used. However, we also
Fig. 4 Activation of human neutrophils by cholinergic mediators. Neutrophils from the a peripheral blood or b sputum of COPD patients were
incubated with aclidinium bromide (Acl), hexamethonium (HEX) or acetylcholinesterase (AChE) for 1 h and then stimulated with carbachol (CCh) or
lipopolysaccharide (LPS) for 6 h. Cell supernatants were collected to measure interleukin (IL)-8 release. The results are expressed as the mean ± SD (n = 4
COPD cell populations in independent experiments run in triplicate). A two-way ANOVA was followed by a post hoc Bonferroni test. *p < 0.05 vs. control
unstimulated cells; #p < 0.05 vs. stimulated cells
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measured expression by RT-PCR and western blot and
obtained similar results. In neutrophils from patients
with stable or exacerbated COPD, the non-neuronal
cholinergic system was over-expressed, with a predomin-
ance of M2 and M4 receptors as well as ChAT, VACHT
and OCT1. These findings suggest that human COPD
neutrophils synthesise intracellular acetylcholine, medi-
ated by ChAT, which is loaded into secretory organelles
by VAChT, thereby making acetylcholine available for se-
cretion through OCT1 membrane channels. Carbachol,
a stable analogue of acetylcholine, activated neutrophils
to release IL-8, whereas inhibition of the latter by aclidi-
nium bromide seemed to confirm a role for functional
muscarinic receptors. The addition of exogenous acetyl-
cholinesterase to eliminate acetylcholine from the cul-
ture medium reduced neutrophil activation by LPS in
blood neutrophils and by CSE in sputum neutrophils,
suggesting that bacterial infection and cigarette smoke
activate acetylcholine release from neutrophils, which in
turn promotes the release of the cytokines and metallo-
proteinases induced by these triggers. However, we did
not detect acetylcholine in the culture medium of hu-
man neutrophils, probably due to the low sensitivity of
the commercial kit used in this study or rapid degrad-
ation by acetylcholinesterases [30] (data not shown).
Similar results have been obtained in alveolar macro-
phages stimulated with carbachol, in which the release
of leukotriene B4 via M3 receptor activation was de-
scribed [15]. In this work, the inhibitory effect of aclidi-
nium bromide appeared to be mediated by M2 blockade,
since the M2 antagonist methoctramine inhibited cyto-
kine release but pFHHSid, an antagonist of M3, did not.
Neutrophils isolated from our COPD patients were less
sensitive to the anti-inflammatory effects of fluticasone
Fig. 5 Effects of aclidinium bromide (Acl) and fluticasone propionate (Flut) on lipopolysaccharide (LPS)-induced corticosteroid modulators. Human
peripheral blood neutrophils isolated from COPD patients were plated on 24-well plates, incubated with Acl, Flut or a combination thereof for 1 h, and
stimulated with LPS for 6 h. Molecular corticosteroid modulators were quantified by RT-PCR using the 2−ΔCt method, with expression of the housekeeping
gene GAPDH serving as an internal control. The results are expressed as the mean ± SD (n= 4 each for cells from healthy controls and COPD patients in
independent experiments with triplicate samples). A two-way ANOVA was followed by a post hoc Bonferroni test. *p< 0.05 vs. control unstimulated cells;
#p< 0.05 vs. Flut monotherapy
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propionate than neutrophils from healthy controls, as pre-
viously reported in a study in which dexamethasone was
the corticosteroid [10]. Fluticasone propionate in combin-
ation with aclidinium bromide exhibited additive anti-
inflammatory effects in the blood and sputum neutrophils
of COPD patients, consistent with the increased anti-
inflammatory effects of budesonide combined with the
anti-muscarinic R,R-glycopyrrolate in LPS-stimulated hu-
man monocytes [31]. The additive effects achieved with
aclidinium bromide and fluticasone propionate can be at-
tributed to M2 receptor antagonism, since methoctra-
mine, but not pFHHSid, increased the anti-inflammatory
effects of fluticasone propionate. However, the involve-
ment of M4 and M5 cannot be ruled out by our data.
M1, M3 and M5 receptors are coupled to the Gq pro-
tein and mediate bronchial contraction by activating
phospholipase Cβ1 (PLC), which leads to the production
of inositol 1,4,5-trisphosphate (IP3); the latter is neces-
sary to activate the release of intracellular calcium stores.
M2 and M4 receptors are coupled to Gi protein and me-
diate PI3K activation and the inhibition of adenylate cy-
clase and cyclic adenosine monophosphate (cAMP) [17].
In this work, both aclidinium bromide and methoctra-
mine suppressed LPS-induced PI3Kδ activity. PI3Kδ is
increased in neutrophils [10] and macrophages [32] from
COPD patients and mediates their corticosteroid in-
sensitivity. Therefore, inhibition of PI3Kδ activity by
aclidinium bromide through the M2 receptor may at
Fig. 6 Effects of aclidinium bromide on glucocorticoid response element (GRE) signal and phosphatidylinositol-3-kinase delta activation (PI3Kδ).
a–d Bronchial epithelial Beas2B cells were transfected with a GRE reporter gene and stimulated with different combinations of aclidinium bromide
(Acl), atropine (Atr), fluticasone propionate (Flut) and the inhibitor of PI3K LY294002. d Beas2b transfected with silencing (siRNA) negative control,
and siRNA for muscarinic receptors M2 and M3 receptors were verified by western blot analysis. e Beas2b cells transfected with the GRE reporter
gene and subjected to siRNA of the genes encoding muscarinic receptors M2 and M3 were stimulated with Flut. The results are expressed as the
mean ± SD of three independent experiments run in triplicate. One-way ANOVA was followed by a post hoc Bonferroni test. *p < 0.05 vs. Flut
monotherapy. f Peripheral blood neutrophils from COPD patients were incubated with Acl for 1 h and stimulated with lipopolysaccharide (LPS)
for 30 min. PI3Kδ activity in human neutrophils from COPD patients. The results are expressed as the mean ± SD (n = 4 COPD cell populations in
independent experiments run in triplicate). A two-way ANOVA was followed by a post hoc Bonferroni test. *p < 0.05 vs. control unstimulated cells;
#p < 0.05 vs. LPS-stimulated cells
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least partially explain the improved effects achieved with
the further addition of fluticasone propionate. cAMP
also increases the anti-inflammatory effects of cortico-
steroids. Although not explored in this work, we previ-
ously showed that, in human fibroblasts, aclidinium
bromide prevents the down-regulation of cAMP induced
by carbachol activation [14], which would also account
for the additive effect of aclidinium bromide in combin-
ation with fluticasone propionate. Further evidence is
provided by the fact that cAMP inducers such as LABAs
and roflumilast enhance the effects of corticosteroids by
elevating cAMP [10, 33].
The anti-inflammatory effect of corticosteroids is me-
diated in part by promoting the nuclear translocation of
GRα to nuclear GRE regions, which in turn increases
the expression of anti-inflammatory genes. In this work,
we demonstrated an increased fluticasone-propionate-
mediated GRE signal by the further addition of aclidi-
nium bromide, which resulted in additive effects on the
stimulation of corticosteroid-inducible genes such as
MKP-1, CRISPLD2 and GILZ. MKP1 dephosphorylates
and inactivates different mitogen-activated kinases such
as ERK1/2 and p38 as part of the anti-inflammatory ef-
fects of corticosteroids. Recent evidence indicated that
the inhibition of GRα via GR-Ser-226 phosphorylation
by p38, ERK1/2 or JNK1 inhibits GRα nuclear transloca-
tion and thus mediates corticosteroid insensitivity in
asthmatics [34, 35]. Accordingly, the additive effects ob-
tained with the combination of aclidinium bromide and
fluticasone propionate in increasing MKP1 and inhibit-
ing p-ERK1/2 and p-p38 could explain the reduced ex-
pression of GR-Ser-226 phosphorylation and therefore
the increased anti-inflammatory effects of the drug
combination. CRISPLD2 is a secreted protein that binds
LPS in humans. Enhanced CRISPLD2 expression by flu-
ticasone propionate down-regulates LPS-activating toll-
like receptor 4 (TLR4) pro-inflammatory responses, thus
perhaps reducing the exacerbations of COPD produced
by infections with gram-negative bacteria [36]. In this
work, LPS was used as the stimulus and its pro-
inflammatory effects were enhanced by cigarette smoke,
mediated in part via TLR4 activation [37]. Thus, the in-
hibition of TLR4 downstream signalling in response to
the increase in CRISPLD2 induced by the combination
of aclidinium bromide and fluticasone propionate may
explain at least some of the anti-inflammatory effects of
the two drugs. The corticosteroid-inducible gene GILZ
inhibits the transcriptional activity of NF-kB and AP-1,
both of which are involved in inflammatory pathways
[38]. By suppressing indices of inflammation, the
increase in GILZ expression and that of other
corticosteroid-inducible genes by the drug combination
could confer protection against bronchoconstriction,
thus limiting airway remodelling. However, the present
work was confined to an in vitro analysis of the potential
clinical benefits of LAMA/ICS combinations and its re-
sults still require clinical corroboration.
Conclusions
Aclidinium bromide attenuates corticosteroid-resistant
neutrophil activation in COPD patients. Additive anti-
inflammatory properties are achieved when it is used
in combination with fluticasone propionate. These
observations provide a scientific rationale for treating
COPD patients with a combination of LAMAs and
corticosteroids.
Fig. 7 Combined aclidinium bromide (Acl) and fluticasone propionate (Flut) shows additive effects in inhibiting the lipopolysaccharide (LPS)-induced
phosphorylation of ERK1/2, p38 and GR-Ser226 and in increasing MKP1 levels. Human peripheral blood neutrophils from COPD patients were incubated
with Acl, Flut or a combination thereof for 1 h and then stimulated with LPS during 30 min. Total protein was extracted for western blotting. The
expression of p-ERK1/2, p-p38 and p-GR-Ser226 was determined as the ratio of the respective non-phosphorylated forms, and that of MKP1 vs. β-actin
expression. Representative images are shown. Data are presented as the mean ± SD (n= 4 COPD cell populations in independent experiments run in
triplicate). A two-way repeated measures ANOVA was followed by post hoc Bonferroni tests: *p < 0.05 vs. the control; #p < 0.05 vs. LPS-stimulated cells.
⊥ p < 0.05 vs. cells treated with drug monotherapy
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Additional files
Additional file 1: Supplementary Table S1. Maximal percentage of
inhibition of IL-8, MMP-9, CCL-5, GM-CSF and IL-1β release from neutrophils
of healthy subjects and COPD patients. Neutrophils were incubated with
aclidinium (Acl; 0.1nM-1 μM), fluticasone (Flut; 0.1nM-1 μM), formoterol (Form;
0.01nM-100nM) or salmeterol (Salm; 0.1nM-1 μM) in response to LPS (1 μg/ml)
or cigarette smoke extract (CSE 5 %). The levels of different cytokines in the
cell supernatant were determined and the maximal percent of inhibitions
were calculated. Values are mean ± SD of 3 independent experiments run in
triplicate. *p< 0.05 vs Healthy values; #p< 0.05 vs Acl group. (DOCX 17 kb)
Additional file 2: Supplementary Figure E1. Effects of formoterol and
salmeterol on pro-inflammatory markers. Concentration-dependent inhibition
of lipopolysaccharide (LPS)-induced cytokines or MMP-9 release by formoterol
(Form) and salmeterol (Salm) from peripheral blood neutrophils of healthy
subjects and COPD patients. Neutrophils were preincubated with Salm
(0.1nM-1 μM) or form (0.01nM-100nM) for 1 h followed by cell stimulation
with LPS (1 μg/ml) for 6 h. Results are expressed as means ± SD of n= 3
(3 cell healthy and 3 cell COPD populations run in triplicate) independent
experiments. Two-way ANOVA was followed by the post hoc Bonferroni test.
*p< 0.05 related to cells from COPD patients; #p< 0.05 related to the basal
values. (TIF 3172 kb)
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